ReviewJournal of neuro-oncology2009
Gene therapy as an adjuvant treatment for malignant gliomas: from bench to bedside.
Review in Journal of neuro-oncology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 36 citations in OpenAlex.
- Expression of eIF4E Gene in Glioma and Its Sensitivity to Oxidative Stress.Oxidative medicine and cellular longevity · 2022Article
- Human iPSC for Therapeutic Approaches to the Nervous System: Present and Future Applications.Stem cells international · 2016Review
- "Footprint-free" human induced pluripotent stem cell-derived astrocytes for in vivo cell-based therapy.Stem cells and development · 2014Article
- Stem cells and gliomas: past, present, and future.Journal of neuro-oncology · 2014Review
- TROP2 expression and its correlation with tumor proliferation and angiogenesis in human gliomas.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2013Article
- Current status of gene therapy for brain tumors.Translational research : the journal of laboratory and clinical medicine · 2013Article
- The art of gene therapy for glioma: a review of the challenging road to the bedside.Journal of neurology, neurosurgery, and psychiatry · 2013Review
- A peptide-mediated targeting gene delivery system for malignant glioma cells.International journal of nanomedicine · 2013Article
- Isthmin inhibits glioma growth through antiangiogenesis in vivo.Journal of neuro-oncology · 2012Article
- Stem cells as therapeutic vehicles for the treatment of high-grade gliomas.Neuro-oncology · 2012Review
- HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis.Journal of neuro-oncology · 2012Article
- Glioblastoma multiforme: novel therapeutic approaches.ISRN neurology · 2012Article
- Intrathecal gene therapy for treatment of leptomeningeal carcinomatosis.Journal of neuro-oncology · 2011Article
- Embryonic stem cell (ESC)-mediated transgene delivery induces growth suppression, apoptosis and radiosensitization, and overcomes temozolomide resistance in malignant gliomas.Cancer gene therapy · 2010Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Malignant brain tumors, including high-grade gliomas, are among the most lethal of all cancers. Despite considerable advances, including multi-modality treatments with surgery, radiotherapy, and chemotherapy, the overall prognosis for patients with this disease remains dismal. Currently available treatments necessitate the development of more effective tumor-selective therapies. The use of gene therapy for brain tumor therapy is promising as it can be delivered in situ and selectively targets brain tumor cells while sparing the adjacent normal brain tissue. In this article, we summarize the laboratory and clinical work using viral, cell-based, and synthetic vectors, as well as other strategies focused on potentiate gene delivery. Although tangible results on patients' survival remains to be further documented, significant advances in therapeutic gene transfer strategies have been made. The enthusiasm of this progress needs to be tempered by the realistic assessment of the challenges needed to be overcome. Finally, as the field of gene delivery progresses, advances must be made in identifying genes and proteins key to the treatment of malignant gliomas. Due to the great heterogeneity of malignant glioma cells, only approaches combining different strategies may be ultimately successful in defeating this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.